Swedish Alzheimer's patients have grown tired of waiting and traveled abroad to receive treatment for the disease in other countries where it is approved, according to official sources. Swedes are being deprioritized in access to the Alzheimer's medicine, major media reports indicate. The handling of the subsidy for the Alzheimer's medicine has drawn criticism, including from the patient association Alzheimerfonden, which co-financed the research behind the medicine.
Health economics researchers have questioned how the authorities have handled the subsidy decision, which has not yet been made, despite one year passing since the European approval. The Alzheimer's medicine is approved within the EU, according to major media. However, the timeline or expected date for Sweden's subsidy decision on the Alzheimer's medicine remains uncertain.